Allogene Therapeutics, Inc. Cash and Restricted Cash
Allogene Therapeutics, Inc. (ALLO) had Cash and Restricted Cash of $48.92 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-12
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $48.92M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $40.60M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $61.98M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $48.11M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $48.92M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $40.60M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $61.98M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $48.11M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $62.62M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $52.75M 10-Q · filed 2026-05-13 |
| 2024-12-31 | $85.51M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $61.53M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $180.96M 10-Q · filed 2025-08-13 |
| 2024-03-31 | $61.33M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $93.45M 10-K · filed 2026-03-12 |
| 2023-09-30 | $79.54M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $165.05M 10-Q · filed 2024-08-07 |
| 2023-03-31 | $120.22M 10-Q · filed 2024-05-13 |
| 2022-12-31 | $72.20M 10-K · filed 2025-03-13 |
| 2022-09-30 | $84.65M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $106.33M 10-Q · filed 2023-08-02 |
| 2022-03-31 | $94.81M 10-Q · filed 2023-05-03 |
| 2021-12-31 | $183.61M 10-K/A · filed 2024-03-14 |
| 2021-09-30 | $199.47M 10-Q · filed 2022-11-02 |
| 2021-06-30 | $232.95M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $246.31M 10-Q · filed 2022-05-04 |
| 2020-12-31 | $192.80M 10-K/A · filed 2024-03-14 |
| 2020-09-30 | $167.59M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $284.68M 10-Q · filed 2021-08-04 |
| 2020-03-31 | $140.19M 10-Q · filed 2021-05-05 |
| 2019-12-31 | $179.43M 10-K/A · filed 2024-03-14 |
| 2019-09-30 | $165.29M 10-Q · filed 2020-11-04 |
| 2019-06-30 | $116.88M 10-Q · filed 2020-08-05 |
| 2019-03-31 | $97.05M 10-Q · filed 2020-05-06 |
| 2018-12-31 | $93.73M 10-K · filed 2022-02-23 |
| 2018-09-30 | $84.08M 10-Q · filed 2019-11-05 |
| 2018-06-30 | $143.93M 10-Q · filed 2019-08-07 |
| 2018-03-31 | $5.00K 10-Q · filed 2019-05-07 |
| 2017-12-31 | $0.00 10-K · filed 2021-02-25 |
| 2017-11-29 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |